X

Trial Profile

Alternating or Combined Therapy With Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated, or Blastic Phases

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axitinib (Primary) ; Bosutinib (Primary)
Indications Chronic myeloid leukaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

10 Nov 2020 Status changed from active, no longer recruiting to discontinued (Terminated per PI's request at the time of CR).
30 Jul 2019 Planned End Date changed from 1 Mar 2021 to 31 Aug 2021.
30 Jul 2019 Planned primary completion date changed from 1 Mar 2021 to 31 Aug 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com